I’m currently looking into unit-dose repackaging policies in hospital pharmacies and would like to compare practices.
Given the limited availability of stability data after repackaging, how do you decide which medicines can or cannot be removed from their original packaging and repackaged? Do you use a blacklist or specific criteria? And what BUD do you apply when product-specific stability data are lacking?
Thanks for sharing your experience!
